Wall Street analyst estimates for Phio Pharmaceuticals Corp. (PHIO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.36 | ||
| 2026-08-06 | $-0.36 | $-0.36 | +0.0% |
| 2026-05-07 | $-0.34 | $-0.24 | -41.7% |
| 2026-03-05 | $-0.15 | $-0.34 | +55.9% |
| 2025-11-13 | $-0.44 | $-0.45 | +2.2% |
| 2025-08-14 | $-0.45 | $-0.36 | -25.0% |
| 2025-05-15 | $-0.41 | ||
| 2025-03-31 | $-0.85 | $-1.23 | +30.9% |
Valuation Ratios
| Price / Book | 0.88 |
| EV / EBITDA | 0.03 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19000 | $15000 | $138000 | $21000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $5.4M | $5.4M | $4.3M | 0 | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $4.6M |
| Gross Profit | -$5.4M | -$5.4M | -$4.2M | $21000 | -$3.7M | -$8.9M | -$7.0M | -$6.3M | -$3.6M | -$4.6M |
| Research & Development | $5.4M | $5.4M | $4.3M | $4.3M | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $4.6M |
| Selling, General & Admin | $3.6M | $4.0M | $3.2M | $4.7M | $5.1M | $4.6M | $4.5M | $4.3M | $3.7M | $4.6M |
| Operating Expenses | $9.0M | $9.4M | $7.5M | $9.0M | $5.1M | $4.6M | $4.5M | $4.5M | $3.7M | $4.6M |
| Operating Income | -$9.0M | -$14.1M | -$7.4M | -$9.0M | -$8.8M | -$13.5M | -$11.5M | -$10.8M | -$7.4M | -$9.2M |
| EBITDA | -$9.0M | -$14.0M | -$7.3M | -$8.9M | -$8.7M | -$13.2M | -$11.4M | -$10.6M | -$7.1M | -$8.7M |
| Interest Expense | 0 | $1000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$9.0M | -$14.1M | -$7.4M | -$8.9M | -$8.8M | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M |
| Income Tax | -$74000 | -$1.6M | $4000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$9.0M | -$12.5M | -$7.4M | -$8.9M | -$8.8M | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M |
| EPS | $-79282.81 | $-32801.22 | $-6218.35 | $-2074.18 | $-207.25 | $-111.32 | $-89.61 | $-46.87 | $-0.91 | $-1.45 |
| EPS (Diluted) | $-79282.81 | $-32801.22 | $-6218.35 | $-2074.18 | $-207.25 | $-111.32 | $-89.61 | $-46.76 | $-0.91 | $-1.45 |
| Shares Outstanding (Diluted) | $113 | $380 | $1184 | $4262 | $42432 | $118684 | $126159 | $231508 | $787466 | $6.0M |
Price
| Price | $1.00 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACXP · APRE · APVO · BCDA · CELZ · GLTO · INAB
Explore sector: Healthcare · Biotechnology
More sections of PHIO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks